• Discover Astex
    • Our Mission & Values
    • Our Leadership Team
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap® PKB/Akt Inhibitor (Oncology)
        • KRAS Oncogene (Oncology)
        • Beroterkib (ASTX029) Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
        • SHP2 (Oncology)
        • P53 tumour suppressor protein (Oncology)
      • Proprietary Products and Programs
        • Tolinapant (ASTX660) Dual IAP Antagonist (T-cell Lymphomas)
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Click to open the search input field Click to open the search input field Search
  • Menu Menu
You are here: Home1 / AT7519 – CDK inhibitor2 / 20073 / 2007 ASH_AT7519 is Active in Leukemia Models and Primary CLL Patient S...

2007 ASH_AT7519 is Active in Leukemia Models and Primary CLL Patient Samples

25 July 2007/in 2007, AT7519 – CDK inhibitor, Products

2007 ASH_AT7519 is Active in Leukemia Models and Primary CLL Patient Samples

https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg 0 0 webadmin https://astx.com/wp-content/uploads/2023/12/New_Home_Logo_RGB.svg webadmin2007-07-25 14:11:472016-11-25 14:12:322007 ASH_AT7519 is Active in Leukemia Models and Primary CLL Patient Samples

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal
  • LinkedIn

Member of the Otsuka Group

A selection of photos on this website
is courtesy of Valerio Berdini

Link to: SuperGen Reports Dosing of First Patient in Phase I Trial of Novel Tyrosine Kinase Inhibitor Link to: SuperGen Reports Dosing of First Patient in Phase I Trial of Novel Tyrosine Kinase Inhibitor SuperGen Reports Dosing of First Patient in Phase I Trial of Novel Tyrosine... Link to: SuperGen Reports 2007 Second Quarter Financial Results Link to: SuperGen Reports 2007 Second Quarter Financial Results SuperGen Reports 2007 Second Quarter Financial Results
Scroll to top Scroll to top Scroll to top
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it.Ok